MilliporeSigma and ReForm Biologic have entered into a global licensing deal that will advance research and development of excipients to manufacture biologics, including qualification activities prior to their commercialization.
MilliporeSigma, ReForm: New licensing deal for excipients
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.